Serologic evaluation of patients receiving procainamide.
This controlled study examined the characteristics of serologic abnormalities in 52 patients receiving procainamide for cardiac arrhythmias, who had no symptoms of a connective tissue disease. Antinuclear antibodies occurred in 43 patients (83%). Significant elevation of antibody binding to single-stranded DNA (mean +/- SEM 30 +/- 2.6%), double-stranded DNA (13 +/- 1.1%), Z-DNA (optical density 0.54 +/- 0.06), and poly A (7.2 +/- 0.6%) was seen (P less than 0.001). Thirty-four patients (65.4%) had antibodies to total histones, most frequently, the H2A/2B dimer. IgG antibodies to H2A/2B correlated with the cumulative procainamide dose. One patient subsequently developed drug-related lupus.
Mongey
A B
AB
Department of Medicine, University of Cincinnati Medical Center, Ohio 45267.
Donovan-Brand
R
R
Thomas
T J
TJ
Adams
L E
LE
Hess
E V
EV
D000368:Aged; D000369:Aged, 80 and over; D000888:Antibodies, Anti-Idiotypic / Q000032:analysis; D000974:Antibodies, Antinuclear / Q000032:analysis*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D004247:DNA / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006657:Histones / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D008177:Lupus Vulgaris / Q000097:blood* / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D011061:Poly A / Q000276:immunology; D011342:Procainamide / Q000009:adverse effects*; D012217:Rheumatoid Factor / Q000097:blood
D000888:Antibodies, Anti-Idiotypic; D000974:Antibodies, Antinuclear; D006657:Histones; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D011061:Poly A; D004247:DNA; D012217:Rheumatoid Factor; D011342:Procainamide